Mediquest Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 03-12-2024
- Paid Up Capital ₹ 7.96 M
as on 03-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -6.52%
(FY 2020)
- Profit -9.30%
(FY 2020)
- Ebitda 124.18%
(FY 2020)
- Net Worth -620.88%
(FY 2020)
- Total Assets 13.46%
(FY 2020)
About Mediquest Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 7.96 M, as per Ministry of Corporate Affairs (MCA) records.
Satish Singh, Rajeevranjan Singh, Sarita Singh, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC281975
- Company No.
281975
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mediquest Pharmaceutical?
Board Members(5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Satish Singh | Director | 02-Jun-2016 | Current |
Rajeevranjan Singh | Director | 14-Dec-2018 | Current |
Sarita Singh | Director | 21-Jun-2018 | Current |
Ranjan Alok | Director | 14-Dec-2018 | Current |
Mousumi Mukherjee | Director | 10-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Mediquest Pharmaceutical.
Mediquest Pharmaceutical Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 6.52% decrease. The company also saw a slight decrease in profitability, with a 9.3% decrease in profit. The company's net worth observed a substantial decline by a decrease of 620.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Mediquest Pharmaceutical?
In 2019, Mediquest Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mediquest Pharmaceutical?
Mediquest Pharmaceutical has a workforce of 8 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediquest Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediquest Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.